Subdural hematoma in patients with systemic cancer

Area of Science:

• Neuro-oncology
• Neurosurgery
• Hematology

Background:

• Subdural hematoma (SDH) is a serious complication in patients with systemic cancer.
• Understanding the causes and outcomes of SDH in cancer patients is crucial for clinical management.

Purpose of the Study:

• To investigate the causes and clinical outcomes of subdural hematoma (SDH) in patients with systemic cancer.
• To differentiate SDH characteristics and prognosis between solid tumors and hematologic malignancies.

Main Methods:

• Retrospective review of medical records for 70 patients with systemic cancer and concurrent subdural hematoma (SDH).
• Analysis of patient demographics, cancer type, causes of SDH (trauma, anticoagulants, coagulopathy, dural metastasis), and outcomes (recurrence, mortality).

Main Results:

• In patients with solid tumors, trauma and anticoagulant use were frequent causes of SDH, associated with a relatively favorable outcome.
• In patients with hematologic cancers, and a subset of solid tumor patients, coagulopathies and dural metastatic involvement were primary causes of SDH.
• Recurrent SDH and mortality due to SDH were significantly higher in the group with hematologic cancers or solid tumors complicated by coagulopathy/metastasis.

Conclusions:

• The etiology and prognosis of subdural hematoma (SDH) in cancer patients vary significantly based on the underlying cancer type.
• Patients with solid tumors and trauma-related SDH generally have better outcomes compared to those with hematologic malignancies or SDH from coagulopathy/metastasis.
• Early recognition of risk factors and prompt management are essential for improving outcomes in cancer patients with subdural hematoma.